Colorectal Cancer in China
Overview
Colorectal cancer develops from adenomatous polyps in the colon or rectum over several years, which makes it one of the most preventable and, when detected early, most curable cancers. Screening colonoscopy is therefore central to care.
Chinese high-volume centers perform robotic and laparoscopic resections with enhanced-recovery protocols that shorten hospital stays, and offer transanal techniques that make sphincter-preserving surgery possible for low rectal tumors.
Symptoms & Signs
Change in bowel habit — diarrhea, constipation or narrower stools — lasting more than a few weeks
Rectal bleeding or blood mixed in the stool
Iron-deficiency anemia and unexplained fatigue
Abdominal discomfort, cramping or bloating
Unexplained weight loss in advanced disease
Polyps themselves are asymptomatic and removed during screening before becoming cancer
Diagnosis
Colonoscopy with biopsy — the definitive diagnostic test
CT of chest, abdomen and pelvis, with PET-CT for selected cases, for staging
Serum CEA tumor-marker measurement for prognosis and follow-up
MRI of the rectum defining tumor depth and margin for rectal cancer planning
MSI/MMR, RAS and BRAF molecular testing guiding targeted therapy
Treatment Options
Laparoscopic or robotic colectomy with complete mesenteric excision
Total mesorectal excision (TME) for rectal cancer, increasingly via transanal (TaTME) approach
Neoadjuvant chemoradiotherapy or total neoadjuvant therapy for locally advanced rectal cancer
Adjuvant chemotherapy for node-positive colon cancer
Targeted therapy (anti-EGFR, anti-VEGF) combined with chemotherapy for metastatic disease
Surgical or ablative treatment of liver and lung oligometastases for long-term control
Advanced Technologies & Novel Drug
da Vinci robotic rectal surgery with precise nerve-sparing dissection
3D laparoscopy and fluorescence (ICG) perfusion assessment of anastomoses
ERAS enhanced-recovery protocols shortening hospital stay
Circulating tumor DNA monitoring after surgery for early relapse detection
Novel immunotherapy for MSI-H tumors and targeted combinations for refractory disease
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Zhongshan Hospital, Fudan University — Shanghai
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- West China Hospital, Sichuan University (Huaxi Hospital) — Chengdu
- Liu Jian Zhong — Colorectal Tumor Department
- Wang Yan Mei — Colorectal Surgery
- Fan Xue Shun — Colorectal Surgery
- Kong Da Lu — Colorectal Tumor Department